There is a new lung cancer treatment on the horizon.
Lung cancer is the leading cause of cancer deaths in the U.S., resulting in more deaths each year than prostate cancer, breast cancer, and colorectal cancers combined. More than 221,200 new cases of lung cancer will be diagnosed in the U.S. this year, representing about 13 percent of all cancer diagnoses.
Historically, lung cancer has been difficult to treat. It is challenging to detect in its early stages and can take years to develop. Often by the time a patient notices symptoms and is diagnosed, the cancer has spread to other parts of the body which makes the disease more complicated to manage.
However, cancer experts are researching potential ways to harness the power of the body’s immune system to help fight cancer. This approach is called Immuno-Oncology or immunotherapy.
Some of the latest findings in Immuno-Oncology will be presented at the upcoming American Society of Clinical Oncology (ASCO®) Annual Meeting in Chicago at the end of the month. ASCO is the premier cancer research meeting in the world, and provides an opportunity for experts to share the latest clinical research in this deadly disease.
New Lung Cancer Treatment
Lung cancer expert David R. Spigel, MD, director, Lung Cancer Research Program at Sarah Cannon Research Institute, joined me recently to share the latest news from ASCO in the fight against lung cancer. Joining him was patient advocate Steven Young, President & COO, Addario Lung Cancer Medical Institute. Steven shared experiences from the patient’s perspective, and explained the burden of this deadly disease.
New Lung Cancer Treatment
Take a look at the interview below.
.
.
To learn more about the latest research in lung cancer treatment, please visit your doctor.
New Lung Cancer Treatment
.
Meet the experts:
David Spigel, MD
Director, Lung Cancer Research Program; Principal Investigator at Sarah Cannon Research Institute
Dr. Spigel joined Sarah Cannon in 2003 and serves as the director of the lung cancer research program where he oversees the design and conduct of clinical research in lung cancer. He also directs Phase II/III research at Tennessee Oncology in Nashville.
Spigel received his bachelor’s degree from Tulane University in New Orleans in 1992, and medical degree from The University of Tennessee in Memphis in 1996. After completing an internal medicine and chief residency at Indiana University Medical Center, he completed a fellowship in hematology and oncology at The Dana-Farber Cancer Institute in Boston. He is board certified in medical oncology.
New Lung Cancer Treatment
Steven Young
President & COO, Addario Lung Cancer Medical InstituteÂ
Since 2008, Young has served as the President of the Addario Lung Cancer Medical Institute (ALCMI), which is a non-profit organization that accelerates the discovery, development, and delivery of new and more effective diagnostic and treatment options for patients in need. The goal of ALCMI is to significantly improve lung cancer patient outcomes and survival.
Young has extensive advocacy experience, having been associated with ALCMI for more than six years and prior to that, working in the blood cancer space with the Multiple Myeloma Research Foundation and Consortium.
New Lung Cancer Treatment
